Table 4 Clinico-pathological parameters and CEA and CA 19–9 serum levels prior to treatment

From: Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study

Clinico-pathological parameters

Total number (n)

CEA measurements (n)

Median CEA [%]; IQR

Spearman’s ρ, P-valueb

CA19-9 measurements (n)

Median CA19-9 [%]; IQR

Spearman’s ρ, P-valueb

All CRC cases

184 (100%)

178 (100%)

  

177 (100%)

  

Localisation

 Caecum

34 (18.5%)

33 (18.5%)

1.600; 2.75

 

33 (18.6%)

11.90; 24.30

 

 Ascending colon

33 (17.9%)

32 (18.0%)

1.700; 3.25

 

32 (18.1%)

13.50; 19.33

 

 Transverse colon

13 (7.1%)

13 (7.3%)

1.800; 3.75

 

13 (7.3%)

10.00; 47.20

 

 Descending colon

10 (5.4%)

8 (4.5%)

2.900; 11.50

 

8 (4.5%)

11.30; 13.20

 

 Sigmoid colon

44 (23.9%)

43 (24.2%)

1.800; 1.50

 

42 (23.7%)

10.35; 12.18

 

 Rectum

43 (23.4%)

42 (23.6%)

1.900; 2.28

P = 0.43

42 (23.7%)

9.900; 8.98

P = 0.73

 Othersc

7 (3.8%)

7 (3.9%)

8.200; 28.30

 

7 (4.0%)

8.100; 18.30

 

Primary tumour (T) category

 Tis

1 (0.5%)

1 (0.6%)

N/A

 

1 (0.6%)

N/A

 

 T1

14 (7.6%)

13 (7.3%)

1.000; 0.95

 

13 (7.3%)

7.500; 10.10

 

 T2

30 (16.3%)

28 (15.7%)

1.550; 1.68

 

27 (15.3%)

11.300; 8.60

 

 T3

103 (56.0%)

101 (56.7%)

1.900; 1.85

ρ = 0.39

101 (57.1%)

11.60; 13.20

ρ = 0.071

 T4

30 (16.3%)

29 (16.3%)

7.700; 18.65

P = 0.001

29 (16.4%)

9.900; 44.55

P = 0.35

 N/Aa

6 (3.3%)

6 (3.4%)

1.550; 3.63

 

6 (3.4%)

6.500; 3.28

 

Regional node (N) category

 N0

97 (52.7%)

95 (53.4%)

1.600; 1.80

 

94 (53.1%)

9.650; 11.45

 

 N1

41 (22.3%)

39 (21.9%)

2.100; 4.00

ρ = 0.33

39 (22.0%)

9.900; 12.40

ρ = 0.27

 N2

27 (14.7%)

27 (15.2%)

2.900; 31.90

P = 0.001

27 (15.3%)

26.70; 43,60

P = 0.001

 Nx

19 (10.3%)

17 (9.6%)

1.500; 2.20

 

17 (9.6%)

8.600; 9.15

 

Distant metastasis (M) category

 M0

159 (86.4%)

154 (86.5%)

1.700; 2.05

 

153 (86.4%)

10.00; 11.75

 

 M1a

18 (9.8%)

17 (9.6%)

2.600; 21.30

P = 0.001

17 (9.6%)

19.80; 105.0

P = 0.026

 M1b

7 (3.8%)

7 (3.9%)

4.400; 36.20

 

7 (4.0%)

28.10; 32.90

 

Histopathological grade

 G1

9 (4.9%)

8 (4.5%)

1.650; 2.13

 

8 (4.5%)

11.65; 10.75

 

 G2

134 (72.8%)

131 (73.6%)

1.800; 1.80

ρ = 0.22

130 (73.4%)

9.650; 12.38

ρ = 0.24

 G3

28 (15.2%)

27 (15.2%)

2.900; 12.30

P = 0.004

27 (15.3%)

17.70; 39.90

P = 0.002

 N/Aa

13 (7.1%)

12 (6.7%)

1.700; 5.98

 

12 (6.8%)

9.950; 9.95

 

Lymphatic invasion (L)

 L0

121 (65.8%)

116 (65.2%)

1.600; 1.80

 

115 (65.0%)

9.200; 11.30

 

 L1

53 (28.8%)

52 (29.2%)

2.550; 6.50

P = 0.001

52 (29.4%)

17.05; 28.25

P = 0.001

 N/Aa

10 (5.4%)

10 (5.6%)

2.000; 9.30

 

10 (5.6%)

9.700; 6.85

 

Vascular invasion (V)

 V0

158 (85.9%)

153 (86.0%)

1.700; 2.00

 

152 (85.9%)

11.30; 14.58

 

 V1

13 (7.1%)

12 (6.7%)

5.05; 30.20

P = 0.031

12 (6.8%)

12.00; 743.55

P = 0.49

 N/Aa

13 (7.1%)

13 (7.3%)

2.100; 9.65

 

13 (7.3%)

9.500; 9.40

 

Surgical margin (R)

 R0

175 (95.1%)

170 (95.5%)

1.800; 2.10

 

169 (95.5%)

11.30; 13.60

 

 R1

6 (3.3%)

5 (2.8%)

8.30; 129.20

P = 0.018

5 (2.8%)

9.90; 2680.00

P = 0.91

 R2

0 (0.0%)

0 (0.0%)

N/A

 

0 (0.0%)

N/A

 

 N/Aa

3 (1.6%)

3 (1.7%)

9.900; N/A

 

3 (1.7%)

6.200; N/A

 

UICC stage

 I

37 (20.1%)

36 (20.2%)

1.350; 1.65

 

35 (19.8%)

10.00; 10.00

 

 II

64 (34.8%)

62 (34.8%)

1.750; 3.28

 

62 (35.0%)

9.050; 11.28

 

 III

48 (26.1%)

47 (26.4%)

2.300; 4,60

ρ = 0.39

47 (26.6%)

14.10; 20.20

ρ = 0.22

 IV

25 (13.6%)

24 (13.5%)

2.850; 33.42

P = 0.001

24 (13.6%)

19.90; 57.10

P = 0.005

 N/Aa

10 (5.4%)

9 (5.1%)

0.900; 1.00

 

9 (5.1%)

8.600; 6.65

 

Extracapsular lymph node extension (ece)

 ece-/N0

129 (70.1%)

123 (69.1%)

1.600; 1.80

 

122 (68.9%)

9.450; 11.25

 

 eced

31 (16.8%)

31 (17.4%)

2.900; 28.30

P = 0.001

31 (17.5%)

23.80; 41.50

P = 0.001

 N/Aa

24 (13.0%)

24 (13.5%)

2.250; 6.25

 

24 (13.6%)

13.30; 10.10

 
  1. Clinico-pathological parameters of the CRC patient cohort (184 patients) and association with CEA and CA 19–9 serum levels. Serum levels prior to treatment were available for 178/184 patients (CEA) and 177/184 patients (CA 19–9)
  2. aN/A: data not available
  3. bP-values refer to the following tests: Wilcoxon–Mann–Whitney test (R0 vs. R1,2; L0 vs. L1; V0 vs. V1; M0 vs. M1a,1b; ece + vs. ece-), Spearman’s rank correlation (T category, N category, UICC stage, G), ANOVA (tumour localisation)
  4. cOthers (descending and sigmoid colon, rectosigmoid transition)
  5. dSignificant feature
Back to article page